Baxter International (NYSE:BAX) Announces Quarterly Earnings Results

Baxter International (NYSE:BAX) issued its earnings results on Thursday. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06, FiscalAI reports. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.91 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.69 EPS.

Here are the key takeaways from Baxter International’s conference call:

• Third-quarter results exceeded expectations: Sales rose 5% organically to approximately $3 billion, with broad-based growth led by Advanced Surgery, drug compounding, and infusion systems. Baxter raised its 2026 organic sales growth outlook to 3%-4% and lifted the low end of adjusted EPS guidance to $2.05-$2.15.
• Cash flow and deleveraging improved: Third-quarter free cash flow was $448 million, bringing year-to-date free cash flow to $705 million. Baxter also completed a $600 million tender offer that retired $854 million of debt and remains confident in reaching approximately 3x net leverage by year-end.
• Operational improvements continued across the portfolio, including better on-time shipments, improved quality metrics, cost savings, and more than 700 Baxter GPS continuous-improvement initiatives completed year to date. Advanced Surgery grew 12%, while HST margins expanded 140 basis points.
• Quality and portfolio actions create near-term pressure: Baxter will discontinue cephalosporin production at its Round Lake facility following supply and FDA warning-letter issues; the products are expected to contribute approximately $50 million in 2026 sales and $30 million in operating income. Management also flagged 2027 headwinds from product exits, the loss of tariff-refund benefits, inflation, tariffs, and the end of Vantive-related TSA services.

Baxter International Stock Performance

BAX traded down $2.00 on Thursday, hitting $23.46. The company had a trading volume of 11,889,629 shares, compared to its average volume of 7,800,397. The stock has a market cap of $12.13 billion, a price-to-earnings ratio of -11.42, a price-to-earnings-growth ratio of 3.83 and a beta of 0.65. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The company’s fifty day moving average price is $24.72 and its 200 day moving average price is $21.34. Baxter International has a 1-year low of $15.73 and a 1-year high of $30.00.

Analysts Set New Price Targets

BAX has been the topic of a number of research analyst reports. Weiss Ratings downgraded shares of Baxter International from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. UBS Group increased their target price on shares of Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Stifel Nicolaus lifted their target price on shares of Baxter International from $19.00 to $24.00 and gave the company a “hold” rating in a research note on Tuesday, July 28th. Wall Street Zen cut shares of Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Finally, Barclays started coverage on shares of Baxter International in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $21.73.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Quarterly results exceeded expectations: Baxter reported adjusted earnings of $0.58 per share, above the $0.51–$0.52 consensus range, while revenue of $2.98 billion surpassed estimates of approximately $2.91 billion. Revenue increased 5% from the prior year. Baxter International Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Growth was broad-based: Segment-wide sales growth helped drive the quarterly beat, and management raised its 2026 financial outlook, providing a more constructive forward-looking signal for investors. Baxter Q3 Earnings Beat and 2026 Outlook Raised
• Positive Sentiment: Baxter also declared its regular quarterly dividend, supporting the stock’s income appeal. Baxter Raises Guidance and Declares Dividend
• Neutral Sentiment: The results indicate improving sales momentum, but investors will likely look for details on the revised 2026 outlook and whether growth can translate into stronger profitability.
• Negative Sentiment: Profitability remains a concern: Quarterly EPS declined from $0.69 a year earlier to $0.58, while Baxter continued to report a negative net margin. Analysts and investors may be discounting the earnings beat because cost and margin pressures remain unresolved. Baxter Reports Third-Quarter 2026 Results

Baxter International Company Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.